Full Text View
Tabular View
Study Results
Related Studies
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
This study has been completed.
Study NCT00798369   Information provided by Novartis

First Received on November 25, 2008.   Last Updated on April 9, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Gout
Additional conditions recognized in this trial
Gout
More general conditions related to this trial
Arthritis
Genetic Diseases, Inborn
Joint Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Musculoskeletal Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Rheumatic Diseases
Interventions listed in this trial
Canakinumab
Triamcinolone acetonide
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Colchicine
Triamcinolone
Triamcinolone diacetate
Triamcinolone hexacetonide
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antimitotic Agents
Antineoplastic Agents
Antirheumatic Agents
Enzyme Inhibitors
Glucocorticoids
Gout Suppressants
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services